Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that sterile fucoidan promotes T cell proliferation but reduces differentiation at higher concentrations and suppresses osteogenic differentiation in co-cultured environments.

This report describes a case of acquired trichorrhexis nodosa in a woman with severe iron deficiency anemia, highlighting a possible link between the two conditions.

This pilot study suggests that high-dose testosterone plus finasteride increased lower-extremity bone mineral density in men with impaired gait and low to low-normal testosterone following chronic incomplete spinal cord injury.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

In this study, clinicians are advised to perform trichography regularly on Pomeranians with HCA, as significant hair abnormalities, especially TN, may affect hair quality; further research is needed to understand the underlying mechanisms and treatment options.

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting postmenopausal women, with unclear causes.

This case report describes a 43-year-old male with alopecia totalis who successfully regrew all his hair after six months of treatment with tofacitinib, with no relapse at one year.

This case report describes a 15-year-old girl with trichorhinophalangeal syndrome type 1 and a rare non-ossifying fibroma in her femur, suggesting a potential link between the genetic condition and bone lesions.

This study identified that patients with compound heterozygous mutations in FOXN1 exhibited severe T-cell lymphopenia but retained normal hair and nail development, indicating a distinct clinical phenotype from classic FOXN1 cases.

This review covers the clinical presentation and challenges in treating frontal fibrosing alopecia in postmenopausal women and concludes that more research is needed to understand its etiology and develop effective treatments.

This study found that NFI-C plays a crucial role in the transition from the telogen to anagen phase of the hair follicle cycle, affecting hair growth initiation in mice.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This review discusses the various treatment options for frontal fibrosing alopecia but reports no definitive results, as no treatment has proven effective in halting hairline recession or promoting hair growth.

In this study, researchers found that p75 neurotrophin receptor signaling affects apoptosis during hair follicle regression in mice, and altering its activity might help manage disorders involving early catagen entry.

In this study, researchers used NIR-II fluorescence imaging to track the survival and migration of EPI-NCSCs in rat models, finding that these stem cells aided in repairing facial nerve defects when applied via acellular nerve allografts.

This study reports a unique case of trichotillomania incognita in an adult female that mimicked female pattern hair loss, highlighting the importance of trichoscopy and histology for accurate diagnosis.

This study found that the peptide TSN6 increased epidermal thickness and promoted hair follicle formation in dermal–epidermal composites grafted onto nude mice, with TSN6-treated composites showing more hair follicles and retained grafts compared to control groups.

This review discusses the mechanisms and pathways of FGFR signalling and its roles in development, disorders, and therapeutic targeting, but reports no new clinical results.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

This study found that in patients with frontal fibrosing alopecia, combining topical tacrolimus with isotretinoin is more effective after four weeks of treatment compared to tacrolimus with finasteride, though both regimens offered some benefit.

This study suggests that finasteride may inhibit testosterone-induced expression of TGF-beta1 and type I procollagen, potentially explaining its role in preventing perifollicular fibrosis in androgenetic alopecia.

This case study reports successful treatment of frontal fibrosing alopecia with daily 2.5mg finasteride in a 77-year-old woman.

This study found that taurine uptake by isolated human hair follicles promoted hair survival and protected against TGF-β1-induced damage in an in vitro setting.

This study developed a novel monoclonal antibody, TYHF-1, which specifically reacts with hair keratins but not with epidermal keratins or various other tissue cells.